telmisartan has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cho, DH; Hwang, YJ | 1 |
2 other study(ies) available for telmisartan and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Activation of AMPK/proteasome/MLCK degradation signaling axis by telmisartan inhibits VSMC contractility and vessel contraction.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Aorta; Doxycycline; Gene Expression Regulation; Leupeptins; Male; Muscle Contraction; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosin-Light-Chain Kinase; Phenylephrine; Phosphorylation; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteolysis; Rats; Rats, Sprague-Dawley; Telmisartan; Vasoconstrictor Agents | 2020 |